ResultsIQ

ResultsIQ › Latest results › Acutaas Chemicals Limited

Acutaas Chemicals Limited Q4 FY25 earnings call summary

NSE: ACUTAAS · BSE: 543349

Earnings call of 2 May 2025, summarised by AI from the filing.

Ami Organics FY25 revenue crossed ₹1,006.9 cr with 40.3% growth; guides 25% revenue growth for FY26 and CDMO revenue of ₹1,000 cr by FY28.

Key takeaways

  1. FY25 revenue ₹1,006.9 cr, 40.3% growth Y-o-Y; PAT ₹160.4 cr, almost double adjusted PAT of last year.
  2. CDMO target ₹1,000 cr by FY28, plan intact; new contracts revenue contribution expected in H2 FY26.
  3. Electrolyte additives Production to start from new brownfield plant at Jhagadia in H2 FY26; capacity 2,000 MT for VC and 2,000 MT for FEC.
  4. Tariff risk U.S. tariff framework and investigation into pharmaceutical imports may lead to future tariff measures.

Original filing on BSE

Acutaas Chemicals Limited Q1 FY27 results

As filed: Revenue ₹330 cr (+59% year on year), EBITDA ₹113 cr (+122% year on year), PAT ₹75.0 cr (+70% year on year), EBITDA margin 34.3% (+966 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹422 cr, EBITDA ₹181 cr, PAT ₹137 cr, EBITDA margin 43.0%. Not scored. No result for the same quarter last year. Share price after the results: +25.2% in 29 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹391 cr, EBITDA ₹154 cr, PAT ₹112 cr, EBITDA margin 39.5%. Not scored. No result for the same quarter last year. Share price after the results: +30.9% in 30 days (Nifty 500: +1.5%).
  • Q2 FY26: Revenue ₹305 cr, EBITDA ₹97.0 cr, PAT ₹73.0 cr, EBITDA margin 31.8%. Not scored. No result for the same quarter last year. Share price after the results: +10.2% in 28 days (Nifty 500: +1.2%).
  • Q1 FY26: Revenue ₹206 cr, EBITDA ₹51.0 cr, PAT ₹45.0 cr, EBITDA margin 24.8%. Not scored. No result for the same quarter last year. Share price after the results: +20.5% in 30 days (Nifty 500: −2.4%).

Past price moves after results do not indicate future moves. Not a recommendation.

Acutaas Chemicals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.